NCT05867550View on ClinicalTrials.gov

To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea

PHASE4CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

March 27, 2023

Study Completion Date

June 10, 2023

Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
DRUG

Rifaximin 550 MG

Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C

DRUG

Mebeverine 135 MG

Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes

DRUG

Psyllium Husk

Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes

DRUG

Amitriptyline Hydrochloride 25 MG

Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes

Trial Locations (1)

Unknown

Bahria University Health Sciences Campus, Karachi

All Listed Sponsors
lead

Bahria University

OTHER